Agios Pharmaceuticals Crecimiento futuro

Future controles de criterios 2/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Agios Pharmaceuticals de 29.4% y 45.1% por año respectivamente. Se prevé que el BPA crezca en un 32.8% al año. Se espera que la rentabilidad financiera sea de -26.5% en 3 años.

Información clave

29.4%

Tasa de crecimiento de los beneficios

32.8%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	0%
Tasa de crecimiento de los ingresos	45.1%
Rentabilidad financiera futura	-26.5%
Cobertura de analistas	Good
Última actualización	23 Feb 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

BMV:AGIO * - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	199	-300	-234	N/A	8
12/31/2025	115	-360	-247	-277	9
12/31/2024	64	-317	-336	-98	9
12/31/2023	27	-352	-315	-296	N/A
9/30/2023	24	-220	-308	-290	N/A
6/30/2023	20	-210	-300	-299	N/A
3/31/2023	19	-218	-309	-307	N/A
12/31/2022	14	-232	-314	-309	N/A
9/30/2022	10	-367	-337	-327	N/A
6/30/2022	6	-369	-350	-341	N/A
3/31/2022	1	-360	-392	-384	N/A
12/31/2021	N/A	-357	-413	-407	N/A
9/30/2021	N/A	-342	-374	-373	N/A
6/30/2021	N/A	-337	-363	-356	N/A
3/31/2021	N/A	-336	-317	-306	N/A
12/31/2020	N/A	-329	-305	-291	N/A
9/30/2020	35	-347	-355	-335	N/A
6/30/2020	61	-374	-370	-352	N/A
3/31/2020	88	-402	-387	-373	N/A
12/31/2019	N/A	-301	-383	-371	N/A
9/30/2019	112	-401	-358	-351	N/A
6/30/2019	102	-389	-337	-329	N/A
3/31/2019	116	-348	-316	-309	N/A
12/31/2018	94	-346	-311	-304	N/A
9/30/2018	74	-343	-312	-305	N/A
6/30/2018	70	-325	-325	-319	N/A
3/31/2018	41	-339	-316	-310	N/A
12/31/2017	43	-315	-290	-285	N/A
9/30/2017	56	-283	N/A	-262	N/A
6/30/2017	53	-269	N/A	-233	N/A
3/31/2017	49	-241	N/A	-17	N/A
12/31/2016	70	-198	N/A	39	N/A
9/30/2016	53	-183	N/A	59	N/A
6/30/2016	50	-160	N/A	83	N/A
3/31/2016	56	-136	N/A	-70	N/A
12/31/2015	59	-118	N/A	-77	N/A
9/30/2015	68	-104	N/A	-54	N/A
6/30/2015	96	-60	N/A	-53	N/A
3/31/2015	91	-46	N/A	-58	N/A
12/31/2014	65	-54	N/A	-59	N/A
9/30/2014	57	-39	N/A	-65	N/A
6/30/2014	30	-55	N/A	-57	N/A
3/31/2014	28	-47	N/A	-71	N/A
12/31/2013	26	-44	N/A	-56	N/A
9/30/2013	25	-49	N/A	-54	N/A
6/30/2013	25	-40	N/A	-51	N/A
3/31/2013	25	-30	N/A	-46	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que AGIO * siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que AGIO * siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que AGIO * siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (45.1% al año) de AGIO * crezcan más rápidamente que los del mercado MX (7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (45.1% al año) de AGIO * crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: AGIO * se prevé que no sea rentable en 3 años.

Agios Pharmaceuticals Crecimiento futuro

Future controles de criterios 2/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

No longer forecast to breakeven

No longer forecast to breakeven

Forecast to breakeven in 2021

Forecast to breakeven in 2021

Agios Pharmaceuticals, Inc. Announces Closing of Oncology Business Sale to Servier

Recent updates

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Agios Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Agios Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Agios Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Agios Pharmaceuticals, Inc. Announces Board Changes

Agios Pharmaceuticals, Inc. Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Appoints Tsveta Milanova as Chief Commercial Officer, Effective Jan. 3, 2023

Agios Pharmaceutical's PYRUKYND® Approves in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

Agios Pharmaceuticals, Inc. Appoints Cecilia Jones as Chief Financial Officer, Effective September 26, 2022

Agios Pharmaceuticals, Inc. Receives Positive Chmp Opinion for Pyrukynd® (Mitapivat) for the Treatment of Pyruvate Kinase (Pk) Deficiency in Adult Patients

Agios Pharmaceuticals, Inc. Announces Resignation of Jonathan Biller as Chief Financial Officer, Effective September 16, 2022

Agios Pharmaceuticals, Inc. Appoints Rahul Ballal and Cynthia Smith to Board of Directors

Agios Pharmaceuticals, Inc. Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent a- and ß-Thalassemia

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces Management Changes, Effective August 8, 2022

Insufficient new directors

Agios Presents New Clinical Data Supporting the Benefits of Pyrukynd® Treatment in Adults with PK Deficiency At European Hematology Association Annual Congress

Agios Pharmaceuticals, Inc. Announces Resignation of Bruce Car as Chief Scientific Officer, effective as of August 1, 2022

Agios Pharmaceuticals, Inc. Announces Management Changes

Agios Pharmaceuticals, Inc. Announces Executive Changes

Agios Pharmaceuticals, Inc. Announces Resignation of Ian T. Clark from the Board

Agios Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 05, 2022

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces FDA Approval of Pyrukynd (Mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency

No longer forecast to breakeven

Insufficient new directors

No longer forecast to breakeven

Agios Pharmaceuticals, Inc. Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition

Chief Commercial Officer Darrin Miles has left the company

Insufficient new directors

Forecast to breakeven in 2021

Forecast to breakeven in 2021

Agios Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Principal Accounting Officer and VP of Accounting, Treasury & Tax Carman Alenson has left the company

Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) dropped from Russell Midcap Value Index

Agios Pharmaceuticals, Inc. Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Study of Mitapivat in Non-Transfusion-Dependent a- and ß-Thalassemia at the European Hematology Association Virtual Congress

Agios Reports Clinical Data Presentations

Agios Pharmaceuticals, Inc. Announces Closing of Oncology Business Sale to Servier

Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

Agios Pharmaceuticals, Inc. Announces the Appointment of Darrin Miles to Role of Chief Commercial Officer

Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused

Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

Servier Pharmaceuticals, LLC entered into a definitive agreement to acquire oncology business from Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) for $2 billion.

Agios Pharmaceuticals, Inc. Announces the Phase 3 ACTIVATE Trial of Mitapivat Achieved its Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused

Agios Pharmaceuticals, Inc. Launches Anemia ID

Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease

Third quarter 2020 earnings released: US$1.43 loss per share

Revenue misses expectations

Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia

Agios Pharmaceuticals, Inc. Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento